Year

Category

2023-01-16

Kancera reports that the FRACTAL-study is on track to report top line results in Q3 2023

Kancera AB (publ) reports that 63 subjects have been recruited to the ongoing FRACTAL-study, a phase IIa study of KAND567 in myocardial infarction patients, which exceeds the initial objective of 60 study subjects in total. Kancera has previously announced...

Read More
2022-12-22

Kancera submits regulatory application to conduct clinical study in ovarian cancer and enters into collaboration with the Nordic Society of Gynaecological Oncology

Kancera AB (publ) today announces that it has submitted the regulatory application to the Swedish Medical Products Agency to conduct clinical studies of KAND567 in ovarian cancer and entered into an agreement with the Nordic Society of Gynaecological Oncology...

Read More
2022-10-27

Interim report third quarter, January 1 – September 30, 2022, Kancera ab (publ.), org.nr. 556806-8851

This is a translation of the interim report published in Swedish at October 26, 2022

Read More
2022-10-27

Kancera reports new preclinical results supporting potential for its ROR1 inhibitor in B-cell malignancies

Kancera AB (publ) reports new preclinical results supporting the potential for KAN571, a ROR1 inhibitor, for treatment of mantle cell lymphoma (MCL), a subtype of B-cell malignancies. Preclinical studies of KAN571 in MCL cell lines show that KAN571 effectively...

Read More
2022-10-20

Kancera reports promising preclinical results from studies of its Fractalkine axis blocking drug candidates in B-cell lymphoma

Kancera AB (publ) reports new preclinical results supporting the potential for the company’s Fractalkine axis blocking candidate drugs to increase the efficacy of standard-of-care drug treatment of B-cell lymphomas, such as chronic lymphocytic leukemia (CLL).

Read More